Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
J Arnt, T Skarsfeldt

Abstract

The pharmacological properties of the novel antipsychotic drugs (APDs) risperidone, sertindole, olanzapine, quetiapine, ziprasidone, remoxipride, and amperozide are reviewed and compared with haloperidol and clozapine. Focus is made on their receptor profiles, their effects in animal models used for evaluation of antipsychotic activity, and extrapyramidal side effects (EPS). In addition, the contrasting actions of these compounds on animal models of cognition, anxiety, and depression are briefly reviewed. The available evidence indicates that novel APDs and clozapine can be differentiated from haloperidol, particularly in models of EPS and cognitive side effects. However, among the group of novel APDs there are many individual differences in models reflecting limbic versus striatal inhibition of dopamine function: clozapine and sertindole show the largest limbic selectivity, followed by quetiapine, ziprasidone, olanzapine and remoxipride, whereas risperidone in many respects has a profile that resembles haloperidol. To date, the results of clinical studies have confirmed the predictions of lower incidence or absence of EPS after administration of novel APDs in doses which demonstrate antipsychotic efficacy.

Citations

Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·V G EvidenteC H Alder
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·J H Friedman, S A Factor
Aug 21, 2001·Biochemical and Biophysical Research Communications·J KangD Rampe
Sep 2, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Marie-Bernadette AssiéAdrian Newman-Tancredi
Feb 15, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Georges VauquelinPhilip Seeman
May 23, 2009·Psychopharmacology·Hugh M MarstonMohammed Shahid
Jan 5, 2011·Psychopharmacology·Katrine FabriciusBjörn Steiniger-Brach
Jun 24, 2006·Wiener klinische Wochenschrift·Julia EnglChristoph Ebenbichler
Apr 15, 2009·Current Treatment Options in Neurology·Frandy Susatia, Hubert H Fernandez
Nov 19, 2013·Clinical Drug Investigation·Alfonso Rodríguez-Martínez, Carlos Guzmán Quilo
Dec 4, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·H H WijnenW M A Verhoeven
Nov 6, 2003·Neuroscience and Biobehavioral Reviews·Christian A Heidbreder, Henk J Groenewegen
Jul 21, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Craig A EricksonChristopher J McDougle
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Shitij KapurMing Li
Jan 16, 2004·Pharmacology, Biochemistry, and Behavior·Andrew J GoudieJon C Cole
Jun 19, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Daniel J MüllerJames L Kennedy
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank P BymasterDavid L Mckinzie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.